Merck: FDA won't approve insomnia drug, wants more studies, lower dose due to safety concerns

  • Article by: LINDA A. JOHNSON , AP Business Writer
  • Updated: July 1, 2013 - 1:25 PM

TRENTON, N.J. — Drugmaker Merck & Co. said Monday that federal regulators have ruled they won't approve high doses of its experimental insomnia medication due to concerns about patient safety. However, the Food and Drug Administration indicated it would approve lower doses of the drug, suvorexant, after Merck does some new studies.

ADVERTISEMENT

Connect with twitterConnect with facebookConnect with Google+Connect with PinterestConnect with PinterestConnect with RssfeedConnect with email newsletters

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT